NCT02829996 - Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

August 19, 2016

Primary Completion Date

May 24, 2017

Study Completion Date

May 31, 2017

Conditions

Primary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)

Interventions

DRUG

trabodenoson 6.0% / latanoprost 0.005% QD

Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

DRUG

trabodenoson 3.0% / latanoprost 0.005% QD

Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

DRUG

trabodenoson 6.0% / latanoprost 0.0025% QD

Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

DRUG

latanoprost 0.005% QD

Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

DRUG

latanoprost 0.0025% QD

Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.

Trial Locations (1)

Inotek Pharmaceuticals Corporation, Lexington